What development phase is TOCERANIB in?

TOCERANIB is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

TOCERANIB

FDA-approved active Small molecule Quality 0/100

Toceranib is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence, leveraging its current revenue streams. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	TOCERANIB
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

PostmenopausAL heaLth And DIseAse (PALLADIA) Study

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TOCERANIB CI brief — competitive landscape report
TOCERANIB updates RSS · CI watch RSS